BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce the Risk of Mortality in Patients with MoCD Type A

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years Clinical trials with NULIBRY or recombinant cPMP showed a meaningful increase in overall survival compared to a natural […]

BridgeBio Pharma, Inc. Reports Fourth Quarter And Full Year 2020 Financial Results And Business Update

–Completed acquisition of Eidos Therapeutics, allowing BridgeBio to deploy its full clinical and commercial infrastructure to develop and plan for potential global commercialization upon regulatory approval of Eidos’ product candidate, acoramidis, a potential best-in-class therapy for patients with amyloidosis cardiomyopathy (ATTR-CM) –New Drug Application (NDA) for infigratinib for the treatment of cholangiocarcinoma accepted by the […]

BridgeBio Pharma To Announce Proof-Of-Concept Data from ADH1 at the Endocrine Society’s 2021 Annual Meeting

– Company to Host Webcast to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 on March 22 at 8:00 a.m. ET SAN FRANCISCO, CA – February 24, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and […]

BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)

SAN FRANCISCO, CA – February 19, 2020 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, and affiliate ML Bio Solutions today announced that the first patient has been dosed in a Phase 2 trial of BBP-418 in patients with LGMD2i. BridgeBio and ML Bio’s BBP-418 is the first-ever oral disease-modifying investigational treatment for LGMD2i. BBP-418 was granted Orphan […]

BridgeBio Pharma, Inc. Announces Pricing of Secondary Offering of Common Stock

PALO ALTO, Calif. – February 12, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the pricing of a secondary public offering of 3,000,000 shares of its common stock at a price per share of $62.50 by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the […]

BridgeBio Pharma, Inc. Announces Launch of Secondary Offering of Common Stock

PALO ALTO, Calif. – February 11, 2021 – BridgeBio Pharma, Inc. (Nasdaq: BBIO) (the “Company,” “we” or “BridgeBio”) announced today the launch of a secondary public offering of 3,000,000 shares of its common stock by selling stockholder KKR Genetic Disorder L.P. The selling stockholder has also granted the underwriters a 30-day option to purchase up […]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Palo Alto, CA, February 5, 2021 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company’s common stock. All of […]

BridgeBio Pharma and Affiliate Venthera Announce Dosing of First Patient in Phase 1/2 Clinical Trial of BBP-681 for Venous, Lymphatic, and Venolymphatic Malformations

First-in-human Phase 1/2 trial in patients with venous malformations (VMs), lymphatic malformations (LMs), and venolymphatic malformations (VLMs) associated with PIK3CA or TEK mutations Clinical trial enrolling patients across multiple sites in the United States PALO ALTO, CA, February 2, 2021—BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Venthera, which is focused on developing new treatment options […]